Characterization of Occult Hepatitis B Virus Infection from Blood Donors in China

Size: px
Start display at page:

Download "Characterization of Occult Hepatitis B Virus Infection from Blood Donors in China"

Transcription

1 JOURNAL OF CLINICAL MICROBIOLOGY, May 2011, p Vol. 49, No /11/$12.00 doi: /jcm Copyright 2011, American Society for Microbiology. All Rights Reserved. Characterization of Occult Hepatitis B Virus Infection from Blood Donors in China Xin Zheng, 1 Xianlin Ye, 2 Ling Zhang, 1 Wenjing Wang, 1 Lifang Shuai, 3 Anqi Wang, 1 Jinfeng Zeng, 2 Daniel Candotti, 4 Jean-Pierre Allain, 1,5 * and Chengyao Li 1 * Department of Transfusion Medicine, Southern Medical University, Guangzhou, China 1 ; Shenzhen Blood Centre, Shenzhen, China 2 ; Guangzhou Military Centre of Disease Control, Guangzhou, China 3 ; National Health Service Blood and Transplant, Cambridge Blood Centre, Cambridge, England 4 ; and Department of Hematology, University of Cambridge, Cambridge, United Kingdom 5 Received 24 January 2011/Returned for modification 7 March 2011/Accepted 10 March 2011 Prevalence and characteristics of occult hepatitis B virus (HBV) infection (OBI) of genotypes B and C prevalent in China have not been extensively explored. Characterization of OBI strains obtained from Chinese blood donors was based on clinical and serological analyses, follow-up testing, and sequence analyses. Twentyeight samples from 165,371 HBV surface antigen (HBsAg)-negative plasmas were confirmed HBsAg negative and DNA positive(hbsag /DNA ), of which 22 were classified as OBIs and 6 as window period infections. The OBI incidence was 1:7,517 in blood donors, whose ages ranged between 20 and 45 years (median, 28 years). OBI donors had normal alanine aminotransferase (ALT) levels and low viral loads ranging between unquantifiable amounts and 178 IU/ml (median, 14 IU/ml). Sequences from 21 basic core promoter/precore (BCP/PC) regions, five whole genomes, and two additional pre-s/s regions from OBI strains were compared to genotypes B and C HBsAg reference strains. Eighty-six percent (6/7) of OBI strains were genotype C. Deletions, insertions, stop codons, and substitutions were detected in 15/21 (71%) core regulatory elements of OBI strains. Critical mutations were found in the core proteins of 5/5 OBI strains in parallel with random substitutions in pre-s/s proteins from 6/7 (86%) OBI strains. Critical mutations in core regulatory elements and core proteins might affect OBI genotype B and C strain replication. That there were few S protein substitutions suggests a minor role of the host immune defenses in OBI occurrence. Hepatitis B virus (HBV) infection is a major threat to human health worldwide, especially to people living in developing countries. The number of HBV carriers with detectable surface antigen (HBsAg) is estimated to be over 300 million globally, while there are around 100 million HBVinfected individuals in mainland China (12). HBV serological testing is widely used in controlling the risk of HBV transmission among people who donate blood or have health examinations in China. However, some studies recently showed HBV DNA at low levels detected in HBsAgnegative individuals, some of whom transmitted HBV infections to recipients of blood transfusions (10). Occult hepatitis B virus infection (OBI) is defined as the detection of HBV DNA in the serum or liver tissue of patients who test negative for HBsAg (15). Currently, testing for HBsAg is performed for screening of HBV infection in blood donors in China, but nucleic acid testing (NAT) is not used. A characterization of OBI strains of genotypes A1, A2, D, and E in comparison with wild-type HBV in samples obtained from European and African blood donors was recently published. The mechanisms for generating OBI strains were * Corresponding author. Mailing address for Chengyao Li: Department of Transfusion Medicine, Southern Medical University, Guangzhou, China. Phone and fax: Mailing address for Jean-Pierre Allain: Department of Hematology, University of Cambridge, Cambridge Blood Centre, Long Road, Cambridge CB2 2PT, United Kingdom. Phone: Fax: jpa1000@cam.ac.uk. X.Z. and Z.Y. contributed equally to this work. Published ahead of print on 16 March mainly related to either imperfect immune control or to genetic viral defects and appeared largely genotype dependent (1, 4). However, analysis of OBI strains of genotypes B and C prevalent in Southeast Asia and China has not been extensively explored, particularly in terms of molecular characterization (14, 20). This study provides new information regarding the prevalence and the molecular analysis of OBI strains of genotypes B and C from samples obtained from asymptomatic blood donors tested in Shenzhen, China. MATERIALS AND METHODS Blood center and sample screening. Donor blood samples were collected by the Shenzhen blood center between August 2003 and December Donor plasmas were individually screened twice for HBsAg, anti-hepatitis C virus (HCV), and anti-hiv antibodies using domestic and international commercial enzyme immunoassays (EIA), including Xiamen Xinchuang HBsAg EIA (Xiamen Xinchuang Scientific Ltd., Xiamen, China), Abbott Auszyme HBsAg (Abbott Laboratories, Abbott Park, IL), Sino-America Huamei anti-hcv EIA (Sino-America Huamei Biotechnology Ltd., Luoyang, China), Ortho anti-hcv EIA (Ortho-Clinical Diagnostics, Inc., Raritan, NJ), Zhuhai Lizhu anti-hiv EIA (Zhuhai Lizhu Biotechnology Ltd., Zhuhai, China), and Melia anti-hiv-1 and -2 EIA (Organon Teknika, Boxtel, Netherlands). The level of alanine aminotransferase (ALT) was also measured for each blood sample with a ReflotronPlus assay (Roche Diagnostics, Mannheim, Germany). Nucleic acid testing. Donor plasmas negative for HBsAg, anti-hcv, and anti-hiv were tested individually for nucleic acids of HBV, HCV, and HIV-1 with a Roche Cobas Ampliscreen assay (Roche), Kehua Real-Time PCR assay (Kehua Biotechnology Ltd., Shanghai, China), or Procleix Ultrio assay (Novartis, Emeryville, CA). Serological testing. HBsAg reactivity was confirmed with a highly sensitive chemiluminescent microplate immunoassay ([CMIA] Architect HBsAg assay; Abbott laboratories) used according to the manufacturer s instructions. Anti- HBs, hepatitis B e antigen (HBeAg), anti-hbe, and anti-hbv core protein 1730

2 VOL. 49, 2011 CHARACTERISTICS OF CHINESE OBI 1731 (HBc) were detected with Kehua HBV EIAs (Kehua). Anti-HBs was quantified in IU/liter with an anti-hbs electrochemiluminescence immunoassay (Roche). HBV DNA quantification, amplification, and sequencing. HBV DNA load was determined by quantitative PCR (qpcr) as described previously (4, 21). Viral DNA was extracted from 0.4 to 1.0 ml of plasma (HighPure; Roche). The HBV basic core promoter/precore region (BCP/PC; nucleotide [nt] 1679 to 1973), the whole genome minus 53 bp (nt 1804 to 1856) in the precore region (3,162 bp), and the pre-s/s region (nt 2802 to 1020) were amplified using nested PCRs sequentially to obtain either the whole genome or fragments of the HBV genome (5, 21). Whole-genome amplicons were cloned in pmd20-t vector (TaKaRa Biotechnology Ltd., Dalian, China), and fragments of pre-s/s were cloned in the original TA cloning kit. Amplified BCP/PC products and two to six clones were sent for sequencing to Shanghai Invitrogen Co., Ltd. (Guangzhou, China). The second WHO international standard for HBV DNA (National Institute for Biological Standards and Control [NIBSC], Potters Bar, United Kingdom) containing IU per vial (NIBSC code 97/750) was kindly provided by Qingtao Song (Xiamen Xinchuang) for quantification of HBV DNA. Occult HBV DNA analyses. Alignment and phylogenetic analyses were performed on a consensus sequence from each OBI plasma sample using the neighborjoining (NJ) method and pre-s/s (1,201 bp) sequences (4). Control HBV wild-type sequences were mostly Chinese strains obtained from HBsAg-positive (HBsAg ) strains selected from the GenBank database. Accession numbers for genotype B strains were AB205119, AB287329, AP011084, AY167089, D00300, DQ448620, DQ448625, DQ993703, DQ993709, EU305548, EU306701, EU306705, EU306706, FJ386582, FJ and FJ787444; for genotype C strains the accession numbers were AP011098, DQ089793, DQ478899, DQ478900, DQ993691, DQ993692, DQ993693, EU306720, EU306721, EU916238, EU916240, EU939540, EU939652, FJ386575, FJ386576, FJ386627, FJ386685, FJ562218, FJ562232, FJ562244, X04615, X75656, and X Diversity was defined as the mean value for a pairwise difference of sequence between OBI and HBV wild-type consensus sequences within the same group, calculated as the number of nucleotide or amino acid differences between two individual sequences (4). Statistical analyses. SPSS software (version 13.0) was used for statistical analyses. Categorical variables were compared by using Fisher s exact test and, for continuous variables, a nonparametric Mann-Whitney test. RESULTS Sample classification and characterization. A total of 165,371 donor plasma samples from Shenzhen Blood Center were screened as HBsAg negative (HBsAg ) with one international and one domestic commercial EIA kit. Thirty-three plasmas were detected as HBV DNA positive (DNA ) by individual-sample NAT. Twenty-eight of 33 plasmas were confirmed as HBsAg and DNA (HBsAg /DNA ) by the CMIA for HBsAg and nested PCR for BCP/PC. Twenty of 33 blood donors with an index sample determined to be HBsAg / DNA were recalled for follow-up testing of HBV infection markers 2 to 221 days after index donation. A total of 22/28 index samples determined to be HBsAg / DNA were classified as OBIs (Table 1). Seromarker-negative SZ2 and SZ9 donors tested positive for HBV DNA by a Roche PCR-enzyme-linked immunosorbent assay (ELISA) and nested PCR in follow-up samples and were classified as seronegative or primary OBIs (1, 15). Donor SZ25 with negative seromarkers was found reactive for both anti-hbs and anti-hbe 25 days after the index sample was obtained (postindex), and this sample was classified as OBI. The other 19 samples were confirmed as OBIs by serological markers or follow-up testing. Donors SZ90 and SZ99 were high-level anti-hbs only ( 428 IU/liter) and had been vaccinated for HBV 6 months and 3 years prior to blood donation, respectively. Four index samples (SZ14, SZ17, SZ23, and SZ200) with no serological markers and a viral load of 200 IU/ml were confirmed HBV window period (WP) infections following seroconversion to HBsAg or HBeAg (1st WP) (Table 2). Two samples (SZ4 and SZ12) carrying anti-hbe and anti-hbc seroconverted to HBsAg and were classified as secondary window period infections (2nd WP). Sample SZ3 that was both anti-hbe and anti-hbc was initially classified as HBsAg by two EIAs but was weakly reactive (0.13 IU/ml) by CMIA and was reclassified as chronic infection. Sample SZ24 was found to be HBsAg but HBeAg and was considered chronic infection. Samples SZ13, SZ20, and SZ21 carrying either anti- HBs or anti-hbc but without confirmed HBV DNA by BCP/PC nested PCR were considered false positives. The prevalence of confirmed OBI was 1:7,517 (22/165,371) in Shenzhen blood donors (Table 1). All 22 participants were between 20 and 45 years old (median, 28 years) and had normal ALT levels ( 40 IU/liter). Seventeen samples (77.3%) were anti-hbc, seven (31.8%) were anti-hbs (five with anti- HBc), five (22.7%) were anti-hbe (all with anti-hbc), and three (13.6%) were negative for all seromarkers at initial testing. Viral load of OBI strains ranged between unquantifiable (defined as 1 IU/ml) and IU/ml (median, 14.4 IU/ml). There was no significant difference in viral load between anti- HBs- or anti-hbe-positive and -negative OBI strains (P or P 0.903, respectively). Phylogenetic analysis of five full-length genome (SZ5, SZ6, SZ7, SZ16, and SZ19) and two additional pre-s/s (SZ26 and SZ92) sequences identified one (14.3%) genotype B (OBI B ) and six (85.7%) genotype C (OBI C ) OBI strains (Table 1). Analysis of regulatory elements of occult HBV sequences. The consensus nucleotide sequences of regulatory elements from OBI B and OBI C strains were compared to consensus sequences from 16 genotype B or 23 genotype C HBsAg strains, respectively. Promoters (for pre-s1, pre-s2/s, core, and X proteins), regulatory sequences (core upstream regulatory sequence [CURS] and direct repeat sequences [DR]), enhancers (ENH), and negative regulatory elements (NRE) were analyzed. DR1, DR2, and NRE were conserved. Significantly higher mean diversity was observed in the S promoter region (SP) and ENH regulatory elements from the OBI C sequence (P to ) but not in CURS, BCP, and X promoter region (XP) sequences between OBI C and HBsAg strains (P to 0.846) (Table 3). Mutations were observed in CURS and BCP regions in 71.4% (15/21) of OBI sequences but less frequently in HBsAg control sequences (Table 4). Thirteen of 21 (61.9%) OBI sequences presented CURS (nt 1643 to 1741) mutations consisting of a deletion, insertion, or single or multiple substitutions. OBI samples SZ22 and SZ92 had one nucleotide deletion at the same site, nt 1689; OBI SZ9 had an insertion of C at nt A total of 11 mutations were detected in the CURS region of 11 OBI strains and were present in several strains at nt 1727, 1730, 1703, 1719, and In the BCP region, mutations were detected at six sites in 8/21 (38.1%) OBI strains, including G1742A (SZ5 and SZ15), A1752G (SZ5, SZ15, SZ16, and SZ18), A1762T and G1764A (SZ6), G1799C or C1799G (SZ5, SZ16, SZ19, and SZ92), and A1846T (SZ91). In the epsilon domain eight OBI strains had mutations, but only T1893A (SZ99) had a possible structural impact on the bulge formation. Analyses of occult HBV core, X, envelope, and polymerase proteins. Seven OBI amino acid sequences were aligned with

3 1732 ZHENG ET AL. J. CLIN. MICROBIOL. TABLE 1. Characterization of OBI strains from China Shenzhen blood donors Sample and no. of days postindex Gender a Age (yr) ALT (IU/liter) b Serological test result or level (IU/ml)c HBsAg Anti-HBc Anti-HBs HBeAg Anti-HBe VL (IU/ml) d Genome (genotype) e SZ2 M Neg Neg Neg Neg 1 BCP/PC 2 Neg Neg Neg Neg Neg Pos SZ9 M Neg Neg Neg Neg 1 BCP/PC 2 Neg Neg Neg Neg Neg Pos SZ25 M Neg Neg Neg Neg 15.2 BCP/PC 25 Neg Neg Pos Neg Pos Pos SZ1 M Pos Neg Neg Neg 32.5 BCP/PC 17 Neg Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Pos Neg Neg Neg 30.2 SZ5 M Pos Neg Neg Pos 13.6 Whole (C) 18 Neg Pos Neg Neg Pos ND 33 Neg Pos Neg Neg Pos Neg Pos Neg Neg Pos ND SZ6 F Pos Neg Neg Neg 23.1 Whole (C) 14 Neg Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Pos Pos Neg Neg 29.1 SZ7 F Pos Neg Neg Neg 57.9 Whole (B) 21 Neg Pos Neg Neg Pos Neg Pos Neg Neg Pos Neg Pos Neg Neg Pos 41.3 SZ10 M Pos Neg Neg 1 BCP/PC SZ11 M Pos 1,000 Neg Neg 26.8 BCP/PC 7 Neg Pos Pos Neg Neg Neg Pos Pos Neg Neg ND 25 Neg Pos Pos Neg Neg ND SZ15 M Pos Neg Neg Neg 19.5 BCP/PC 15 Neg Pos Neg Neg Neg ND 930 Neg Pos Neg Neg Pos Neg Pos Pos Neg Pos ND SZ16 M Pos Neg Neg 28.9 Whole (C) 162 Neg Pos Pos Neg Neg ND 464 Neg Neg Pos Neg Pos Pos SZ18 M Pos Neg Neg Neg 1 BCP/PC SZ19 F Pos Neg Neg 69.2 Whole (C) 68 Neg Pos Pos Neg Neg ND 105 Neg Pos Pos Neg Neg ND SZ22 M Pos Neg Neg Neg 6.8 BCP/PC 35 Neg Pos Neg Neg Pos Pos SZ26 M Pos 9.83 Neg Pos 17.4 Pre-S/S (C) SZ27 F Pos Neg Neg Pos 1 BCP/PC SZ28 M Pos Neg Neg Neg 1 SZ29 M Pos Neg Neg Pos BCP/PC SZ91 M Pos Neg Neg Pos 1 BCP/PC SZ92 F Pos Neg Neg Neg 25 Pre-S/S (C) SZ90 f M Neg Neg Neg 1 BCP/PC SZ99 f M Neg Neg Neg 1 BCP/PC Median a M, male; F, female. b ALT level was tested by ReflotronPlus (Roche) in Nanfang hospital, Guangzhou, China. c Serological markers of HBV except HBsAg were detected initially by Kehua HBV EIAs and retested by Architect HBsAg in Nanfang hospital. An HBsAg level of 0.05 IU/ml was considered negative. Anti-HBs was quantified in IU/liter by the Cobas anti-hbs electro-chemiluminescence immunoassay (Roche) in Nanfang hospital. Results in boldface indicate seroconversion during follow-up. Neg, negative; Pos, positive. d Viral load was quantified by qpcr against an international HBV standard. A value of 1 IU/ml indicates a sample with no threshold cycle value but confirmed by nested PCR (Pos). ND, not done. e OBI genomes were amplified by nested PCRs and sequenced by Invitrogen. The whole genome or fragments of HBV DNA were amplified by the nested PCRs, and genotyping was phylogenetically performed from pre-s/s sequences aligned with references. ND, not done. f Donors of index sample SZ90 and SZ99 were vaccinated 6 and 36 months prior to indexing, respectively. the genotype B or genotype C HBsAg control strains. The mean number of amino acid substitutions in pre-c/c, pre-s/s, and polymerase (Pol) regions from the OBI C sequence was higher than in wild-type strains (P to ) (Table 3). In the precore region of five OBI strains, SZ7 had a V17F mutation, and SZ16 had a stop codon at amino acid (aa) 28. Critical mutations in the core region of all five OBI strains associated with B cell, T helper (Th) cell, and cytotoxic T lymphocyte (CTL) epitopes might theoretically influence immunological HBV epitope recognition (Fig. 1) (3, 16). The common mutations I97(L/T) (SZ7, SZ6, and SZ19), P130(T/S) (SZ6 and SZ16), S87G (SZ7 and SZ6), and P135(S/Q) (SZ7

4 VOL. 49, 2011 CHARACTERISTICS OF CHINESE OBI 1733 TABLE 2. Classification of HBV DNA yield from non-obi index samples Infection classification, sample, and no. of days postindex Gender a Age (yr) ALT (IU/liter) b Serological test result or level (IU/ml)c HBsAg Anti-HBc Anti-HBs HBeAg Anti-HBe VL (IU/ml) d Genome (genotype) e 1st WP SZ14 F Neg Neg Neg Neg BCP/PC 12 Neg Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Pos Pos Neg Neg ND SZ17 M Neg Neg Neg Neg Whole (C) 45 Neg Neg Neg Pos Pos 23.2 SZ23 M Neg Neg Neg Neg 675 Whole (B) 13 Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg Neg Pos Pos 85 SZ200 F Neg Neg Neg Neg Whole (B) 5 Neg Neg Pos Pos Pos 732 2nd WP or chronic SZ4 M Pos Neg Neg Pos 51.8 BCP/PC 21 Neg Pos Neg Neg Pos ND 45 Pos Pos Neg Neg Pos ND 91 Pos Pos Neg Neg Pos ND 156 pos Pos Neg Neg Pos ND SZ12 M Pos Neg Neg Pos 1 8 Pos Pos Neg Neg Pos Pos SZ3 M Pos Neg Neg Pos Whole (B) 38 Pos Pos Neg Neg Pos Neg Pos Pos Neg Pos ND 121 Neg Pos Pos Neg Pos ND 166 Neg Pos Pos Neg Pos ND 221 Neg Pos Pos Neg Pos ND SZ24 F Pos Pos Neg 7,321 Whole (C) False positive SZ13 M Pos Neg Neg Neg Neg SZ20 F Neg Pos Neg Neg Neg SZ21 F Neg Pos Neg Neg Neg a M, male; F, female. b ALT level was tested by ReflotronPlus (Roche) in Nanfang hospital, Guangzhou, China. c Serological markers of HBV except HBsAg were detected initially by Kehua HBV EIAs and retested by Architect HBsAg in Nanfang hospital. An HBsAg level of 0.05 IU/ml was considered negative. Anti-HBs was quantified in IU/liter by the Cobas anti-hbs electro-chemiluminescence immunoassay (Roche) in Nanfang hospital. Results in boldface indicate seroconversion during follow-up. Neg, negative; Pos, positive. d Viral load was quantified by qpcr against an international HBV standard. A value of 1 IU/ml indicates a sample with no threshold cycle value but confirmed by nested PCR (Pos). ND, not done. e OBI genomes were amplified by nested PCRs and sequenced by Invitrogen. The whole genome or fragments of HBV DNA were amplified by the nested PCRs, and genotyping was phylogenetically performed from pre-s/s sequences aligned with references. and SZ5) were found in 5/5 (100%) core regions of OBI strains. A specific substitution of L16I, S21L, S26A, P50H, L55I, L60V, M66V, L95I, or T142M was present in the core regions of all sequenced OBI strains but not of WP or chronic infection wild-type HBV strains. In the X region, a mutation of A1762T in BCP led to a substitution of K130M in SZ6. Mutation V88(A/N) was detected in SZ6 and SZ19, and V5L and Q87G were detected in SZ19. One nucleotide deletion at nt 1689 and insertion at nt 1716 in the CURS regions caused an X protein open reading frame (ORF) shift and aberrant translation in OBI samples SZ22, SZ92, and SZ9. Mutations in the pre-s/s region of OBI strains were examined with regard to the known epitopes of CTL, Th, and B cells and the major hydrophilic region (MHR) and a determinant (Fig. 2) (4, 7, 14). OBI MHR and a regions were relatively conserved, and no hot spot mutations were found. Few mutations occurred at sites of subtype conversion of adw and adr corresponding to genotypes B and C. Substitutions I110L and I126T were found in samples SZ7 (OBI B ) and SZ5 and SZ6 (OBI C ), and A159V in SZ7 was presumably related to subtype (Fig. 2D). SZ5 presented substitutions T118M and W165R in MHR. Frequent substitutions were observed in OBI strain S protein at aa 2 to 5 in 4/7 (57%) (SZ7, SZ16, SZ19, and SZ26), in the middle position at aa 88 to 104 within CTL epitope clusters 9 and 10 in 4/7 (57%) OBIs (Fig. 2C), and at C-terminal aa 210 to 225 within the CTL epitope clusters 13 and 14 in 6/7 (85.7%) OBI strains (Fig. 2D). Similarly, frequent substitutions were found in pre-s2 protein at the initial position of aa 5 to 9 within CTL epitope cluster 2 overlapping B-cell epitope cluster 8 from 5/7 (71.4%) OBI strains (Fig. 2B). SZ7 and SZ5 had a pre-s2 mutated start codon. SZ92 had two mutations (pre-si84v and pre-sa90v) in pre-s1 that were also found in SZ7, SZ5, SZ6, and SZ16 (Fig. 1A). The mass random substitutions in the polymerase regions of OBI C were observed at a frequency ranging from 11 to 47

5 1734 ZHENG ET AL. J. CLIN. MICROBIOL. TABLE 3. Intra- and intergroup diversity analyses between OBI C and HBsAg sequences a Regulatory region sequence diversity Protein sequence diversity Genome region b OBI C (n 4) HBsAg (n 23) P value Genome region c OBI C (n 4) HBsAg (n 23) ENH1 6.0 (4 9) 2.8 (0 10) Pre-S/S 11.7 (2 22) d 3.6 (0 14) SP (4 23) 6.2 (1 19) Pre-S1 4.3 (2 7) 0.7 (0 3) SP2 9.0 (5 17) 2.7 (0 9) Pre-S2 0.7 (0 1) 0.9 (0 7) S 7.0 (0 14) 1.9 (0 6) ENH2 6.0 (4 10) 2.7 (0 7) MHR 0.7 (0 3) 0.4 (0 1) CURS 3.0 (2 4) 1.3 (0 4) Pre-C/C 3.5 (2 5) 1.5 (0 5) BCP 1.5 (0 3) d 1.4 (0 4) Pol 23.3 (11 47) 8.9 (2 35) Pol (RT) 4.5 (2 7) 1.5 (0 5) XP 2.5 (1 3) 2.2 (0 5) X 8.0 (5 15) 3.0 (0 7) a Regions with regulatory functions in HBV are presented separately. Average intragroup diversity was calculated as the number of nucleotide (regulatory region sequences) or amino acid (protein sequences) substitution differences between OBI and reference sequences. The range for frequency of nucleotide or amino acid substitutions is in parentheses. n, number of complete sequences from OBI C or references used in analysis (except as noted). The difference of mean diversity between OBI C and reference sequences was calculated as the P value by Fisher s Exact test. b SP1 (nt 2219 to 2780) and SP2 (nt 2809 to 3152), promoters for pre-s1 and pre-s2/s; XP (nt 1239 to 1376), promoter for X region; CURS (nt 1643 to 1741), core upstream regulatory sequence; BCP (nt 1742 to 1849), basal core promoter; ENH2 (nt 1627 to 1774), enhancer II; ENH1 (nt 1071 to 1238), enhancer I. c MHR, major hydrophilic region of S protein; Pol, polymerase; Pol (RT), reverse transcriptase; X, HBx. d n 6. P value (Table 3), and no well-documented hot spot mutations were found in YMDD and FLLA motifs. DISCUSSION The prevalence of HBsAg in the Chinese population has declined to 7.2% due to nationwide HBV vaccination, but approximately 100 million HBV chronically infected individuals live in China (12). The new issue of occult HBV infection uncovered by NAT has become a concern in transfusion and in patients although little is known of OBI in China, where genotype B and genotype C are dominant (12, 20). The epidemiology of HBV infection in the Shenzhen blood donor population is somewhat reflective of that in China as a whole, except for a lower prevalence of HBsAg (12). The prevalence of OBI cases in Shenzhen was therefore expected TABLE 4. Site mutations in core promoter of OBI strains Sample and or genotype CURS (nt ) sequence at position: a BCP (nt ) sequence at position: a HBsAg G/A T/C A A A T T T G A C/A T/A G/C G A A G G/C A B/C b SZ2 NA NA G T G SZ5 (C) /T /G A G /G SZ6 (C) G T /G T A SZ7 (B) A/ SZ9 NA NA C b SZ10 NA NA SZ11 NA NA C SZ15 NA NA A G SZ16 (C) /C /T /G G /G SZ18 NA NA G SZ19 (C) /G /T /T /G /G SZ22 NA NA X c SZ25 NA NA SZ26 (C) NA NA T SZ27 NA NA SZ28 NA NA A SZ29 NA NA SZ90 NA NA SZ91 NA NA G T SZ92 (C) NA NA X c /T /G /G SZ99 NA NA a Positions of mutation sites within CURS and BCP are presented according to nucleotide numbering from EcoRI. NA, not available for nt 1643 to 1678 from BCP/PC amplicons of 16 OBI strains. HBsAg B/C represents the nucleotide consensus sequence (in boldface) of genotype B or C (B/C) reference strains; their average diversity rates are 0.82% and 1.4%, respectively. The site mutations of OBI strains are indicated at genotype B/C positions of the references. The consensus at nt 1752 was 95.7% (22/23) nucleotide A within genotype C and 43.8% (7/16) A or 56.2% (9/16) G within genotype B. b C insertion in OBI SZ9. c X, deletion.

6 VOL. 49, 2011 CHARACTERISTICS OF CHINESE OBI 1735 FIG. 1. Mutations in core proteins of OBI strains corresponding to immune epitope clusters of CTL, B and Th cells. Epitope clusters were from previous descriptions in HBV infections (3, 16). OBI mutations in the core regions are shown; arrows indicate the epitope clusters. The scale represents the amino acid length of the HBV core protein. The numbers at the ends of the epitopes indicate the start and ending amino acid positions for each epitope. to be lower than average in China, but the frequency of 1:7,517 was similar to frequencies reported (median 1:9,819 and 1:8,209) in European or South African blood donors (1, 4). This is surprising considering a lower prevalence in Europe and a similar level in South Africa. In Hong Kong, close geographically to Shenzhen, 80 OBI cases were identified in 357,440 blood donations, or 1:4,468, using the Novartis Ultrio screening method for individual donations. This apparently higher frequency might be related to a higher sensitivity of the screening method (6). The ratio of male to female donors infected with OBI was 3.4:1 (17:5). The median age of 28 years of donors with OBI reflected the blood donor population in Shenzhen but was considerably lower than that of European blood donors with OBI of genotype A2 or D and of South African donors with OBI of genotype A1 (1, 4). As elsewhere, donors with OBI had normal ALT levels and viral loads below 200 IU/ml (median, 14.4 IU/ml) and carried anti-hbc (77.3%) with anti-hbs or anti-hbs only (9%). Compared to European data, the association of anti-hbc and anti-hbs appears less frequent in Shenzhen s donors but primary OBI is more frequent (4). The availability of follow-up samples from 20/30 samples was of considerable help in ensuring the classification of samples and informing the donors, separating OBIs from window period and doubtful chronic infections, and, within OBIs, distinguishing primary OBIs from other types (Tables 1 and 2). Among the latter, follow-up data showed the relative stability of HBV DNA detectability and load (Table 1). Genomic amplification was relatively unsuccessful (12/30 for pre-s/s) in the context of low, often not quantifiable, viral load. Therefore, the genotype was determined in only 27% of OBI strains. Mutations in core regulatory elements involved in viral replication were described previously (8, 13). Compared to HBsAg strains, deletions, insertions, and substitutions at single or multiple sites were observed in the CURS and BCP (15/21) regions of OBI strains (Table 4). Mutations A1752G and A1762T (five OBI strains) were found in TATA box-like regulatory elements (TA1 to TA4). Mutation of both A1762T and G1764A was found in only one OBI C (SZ6) strain, a lower frequency than reported in OBI E (44.4%) (21). Synthesis of both pregenomic and 5 -terminally extended precore RNA is controlled by the core regulatory elements including ENH2, CURS, and BCP; given the overlapping arrangement of ORFs, every single mutation can thus influence more than one function of the corresponding nucleotide sequence during viral RNA transcription. Mutations in OBI strains in core regulatory elements that decrease or abolish viral replication, RNA transcription, or production of precore/core protein and secreted HBe might be responsible for low viral load in OBI B and OBI C strains. The mutations of core protein in HBV infection have been reported associated with not only severe liver disease but also low secretion of HBV virions and immune escape epitopes at Th and CTL levels (3, 11, 16). Mutations of OBI core proteins (Fig. 1) showing amino acid substitutions in the CTL epitope clusters 18 to 27, 88 to 96, and 141 to 151 might constitute escape epitopes and contribute to the persistence of HBV infection despite reducing viral fitness (16). The CTL epitope at positions 18 to 27 is restricted by HLA-A2, but the potential impact of substitutions at position 21 and 26 is not known (2). Similarly, CTL epitopes at positions 88 to 96 and 141 to 151 are restricted by HLA-A11 and HLA-Aw68, respectively (9). Substitution L60V (SZ5) was previously described as related to low-level production of HBV virions (16). Mutations of I97(L/T) and P130T were identified in 60% (3/5) and 40% (2/5) OBI strains. I97L was reported responsible for secretion of immature HBV core, but this phenomenon could be offset by P130T mutation (18, 19). The function of X protein could be influenced by the deletion, insertion, and substitutions of core regulatory elements (Table 4) because the X gene overlaps with the enhancer and core promoter regions. Two important domains between aa 52 to 65 and 88 to 154 of HBx have an enhancing effect on HBV transcription and replication (17). At the protein level, substitution K130M caused by mutation A1762T in BCP (SZ6) was

7 1736 ZHENG ET AL. J. CLIN. MICROBIOL. FIG. 2. Alignments of deduced amino acid sequences of pre-s/s from OBI strains compared to the consensus sequence of a genotype B or C HBsAg strain. Alignments of pre-s/s were examined for pre-s1(a), pre-s2 (B), S (C), and (D) MHR and a region within the S protein. Numbers above the reference sequences indicate epitope clusters (4, 7, 14). Amino acids identified by one-letter code. Dashes indicate identity with the reference consensus sequence for genotype B or C shown on top of each sequence. Amino acid residue K in bold in the reference sequence indicates an HBV serotype-specific amino acid. MHR amino acid mutations in italics may affect serotype or subtype of HBV. observed; other substitutions, V5L, Q87G, and V88(A/N), were involved in 40% (2/5) of OBI strains (SZ19 and SZ6); V88(A/N) and K130M were located in the functional domains of the X protein, but their specific effect on HBV replication is not identified. In the present study, the diversity of pre-s1 and pre-s2 at the nucleotide and protein levels of OBI genotypes B and C was significantly higher than in control HBsAg strains (P ) (Table 3). However, most mutations appeared to be random substitutions. In contrast, the MHR of OBI B and OBI C strains was essentially wild type, particularly in loops 3 and 4 (Fig. 2D). This pattern does not suggest a major impact of immune selection in genotype B and C OBI strains although only a small number of cases was examined; these findings contrast with findings in European genotype A2 and D but are rather similar to findings in African genotype A1 or E OBI strains (1, 4). The relatively high frequency of critical mutations in the precore/core region potentially affecting viral replication and the virtual absence of mutations affecting the pre-s and S proteins suggest that the main mechanism leading to OBI in Shenzhen might be poor viral replication rather than ineffective immune control. ACKNOWLEDGMENTS This work was supported by the National Basic Research Program of China (973 program numbers 2007CB and 2010CB530204) and Guangdong Research Initiating Funding for talent from overseas. We thank the staffs of Shenzhen Blood Center and Qingtao Song for their contribution to the study. We have no conflicts of interest to report.

8 VOL. 49, 2011 CHARACTERISTICS OF CHINESE OBI 1737 REFERENCES 1. Allain, J. P., et al Characterization of occult hepatitis B virus strains in South African blood donors. Hepatology 49: Bertoletti, A., et al Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J. Exp. Med. 180: Bozkaya, H., B. Ayola, and A. S. Lok High rate of mutations in the hepatitis B core gene during the immune clearance phase of chronic hepatitis B virus infection. Hepatology 24: Candotti, D., et al Characterization of occult hepatitis B virus from blood donors carrying genotype A2 or genotype D strains. J. Hepatol. 49: Candotti, D., O. Opare-Sem, H. Rezvan, F. Sarkodie, and J. P. Allain Molecular and serological characterization of hepatitis B virus in deferred Ghanaian blood donors with and without elevated alanine amino transferase. J. Viral Hepat. 13: Choi, W. C., et al Window period and occult HBV infection among blood donor population in Hong Kong, p Abstr. 20th Reg. Cong. Int. Soc. Blood Transfusion, 14 to 18 November 2009, Nagoya, Japan. International Society of Blood Transfusion, Amsterdam, Netherlands. 7. Desmond, C. P., A. Bartholomeusz, S. Gaudieri, P. A. Revill, and S. R. Lewin A systematic review of T-cell epitopes in hepatitis B virus: identification, genotypic variation and relevance to antiviral therapeutics. Antivir. Ther. 13: Guarnieri, M., et al Point mutations upstream of hepatitis B virus core gene affect DNA replication at the step of core protein expression. J. Virol. 80: Khakoo, S. I., et al Cytotoxic T lymphocyte responses and CTL epitope escape mutation in HBsAg, anti-hbe positive individuals. Gut 47: Kleinman, S. H., N. Lelie, and M. P. Busch Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion 49: Le Pogam, S., T. T. Yuan, G. K. Sahu, S. Chatterjee, and C. Shih Low-level secretion of human hepatitis B virus virions caused by two independent, naturally occurring mutations (P5T and L60V) in the capsid protein. J. Virol. 74: Liang, X., et al Epidemiological serosurvey of hepatitis B in China: declining HBV prevalence due to hepatitis B vaccination. Vaccine 27: Liu, C. J., et al Hepatitis B virus basal core promoter mutation and DNA load correlate with expression of hepatitis B core antigen in patients with chronic hepatitis B. J. Infect. Dis. 199: Mu, S. C., Y. M. Lin, G. M. Jow, and B. F. Chen Occult hepatitis B virus infection in hepatitis B vaccinated children in Taiwan. J. Hepatol. 50: Raimondo, G., et al Statements from the Taormina expert meeting on occult hepatitis B virus infection. J. Hepatol. 49: Sendi, H., et al CTL escape mutations of core protein are more frequent in strains of HBeAg negative patients with low levels of HBV DNA. J. Clin. Virol. 46: Tang, H., et al The transcriptional transactivation function of HBx protein is important for its augmentation role in hepatitis B virus replication. J. Virol. 79: Yuan, T. T., and C. Shih A frequent, naturally occurring mutation (P130T) of human hepatitis B virus core antigen is compensatory for immature secretion phenotype of another frequent variant (I97L). J. Virol. 74: Yuan, T. T., P. C. Tai, and C. Shih Subtype-independent immature secretion and subtype-dependent replication deficiency of a highly frequent, naturally occurring mutation of human hepatitis B virus core antigen. J. Virol. 73: Yuan, Q., et al Molecular characteristics of occult hepatitis B virus from blood donors in southeast China. J. Clin. Microbiol. 48: Zahn, A., et al Molecular characterization of occult hepatitis B virus in genotype E-infected subjects. J. Gen. Virol. 89:

Diagnostic Methods of HBV and HDV infections

Diagnostic Methods of HBV and HDV infections Diagnostic Methods of HBV and HDV infections Zohreh Sharifi,ph.D Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine Hepatitis B-laboratory diagnosis Detection

More information

Mutants and HBV vaccination. Dr. Ulus Salih Akarca Ege University, Izmir, Turkey

Mutants and HBV vaccination. Dr. Ulus Salih Akarca Ege University, Izmir, Turkey Mutants and HBV vaccination Dr. Ulus Salih Akarca Ege University, Izmir, Turkey Geographic Distribution of Chronic HBV Infection 400 million people are carrier of HBV Leading cause of cirrhosis and HCC

More information

Frequency of occult hepatitis B in HBsAg seronegative blood donors in a tertiary care hospital in kerala,south India.

Frequency of occult hepatitis B in HBsAg seronegative blood donors in a tertiary care hospital in kerala,south India. Frequency of occult hepatitis B in HBsAg seronegative blood donors in a tertiary care hospital in kerala,south India. Cinzia Keechilot, Veena Shenoy 1,V Anil kumar 2,Lalita Biswas 3. MBBS student * Transfusion

More information

ISBT TTI WP HBV safety subgroup. Review and update

ISBT TTI WP HBV safety subgroup. Review and update ISBT TTI WP HBV safety subgroup Review and update Distribution of dominant HBV genotypes countries & centres participating in HBV studies A2/A1 0.1-0.5 A2 D 0.1-8 B/C F 1-5 E 12-25 5-12 A1 4-8 A2/C HBV

More information

Originally published as:

Originally published as: Originally published as: Ratsch, B.A., Bock, C.-T. Viral evolution in chronic hepatitis B: A branched way to HBeAg seroconversion and disease progression? (2013) Gut, 62 (9), pp. 1242-1243. DOI: 10.1136/gutjnl-2012-303681

More information

Challenges in HBV detec1on in blood donors

Challenges in HBV detec1on in blood donors Challenges in HBV detec1on in blood donors Jean- Pierre Allain Dept Haematology, University of Cambridge, UK Phylogene1c analysis of human and ape HBV over 1me of evolu1on (Pareskevis et al, Hepatology

More information

Diagnostic Methods of HBV infection. Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO)

Diagnostic Methods of HBV infection. Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO) Diagnostic Methods of HBV infection Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO) Hepatitis B-laboratory diagnosis Detection of HBV infection involves

More information

HBV PUBLIC HEALTH IMPLICATIONS

HBV PUBLIC HEALTH IMPLICATIONS جزايری دکتر سيد محمد آزمايشگاه ھپاتيت B -دانشکده بھداشت ويروس شناسی- گروه دانشگاه علوم پزشکی تھران کنگره ارتقا کيفيت- ١٣٩٢ HBV PUBLIC HEALTH IMPLICATIONS 2 billion people have been infected by HBV worldwide.

More information

HEPATITIS B: are escape mutants of concern?

HEPATITIS B: are escape mutants of concern? VACCINATION: AN EVOLUTIONARY ENGINE FOR SPECIES? Fondation Mérieux Conference Centre Veyrier-du-Lac, France November 25-27, 2013 HEPATITIS B: are escape mutants of concern? Alessandro ZANETTI Department

More information

Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation

Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation BRIEF REPORT Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation Man-Fung Yuen, 1 Erwin Sablon, 2 Danny Ka-Ho Wong, 1 He-Jun Yuan, 1 Benjamin Chun-Yu Wong, 1 Annie On-On Chan, 1 and

More information

The Alphabet Soup of Viral Hepatitis Testing

The Alphabet Soup of Viral Hepatitis Testing The Alphabet Soup of Viral Hepatitis Testing August 18, 2011 Patricia Slev, PhD, DABCC Medical Director, Serologic Hepatitis and Retrovirus Laboratory, ARUP Laboratories Assistant Professor of Pathology,

More information

Rama Nada. - Malik

Rama Nada. - Malik - 2 - Rama Nada - - Malik 1 P a g e We talked about HAV in the previous lecture, now we ll continue the remaining types.. Hepatitis E It s similar to virus that infect swine, so its most likely infect

More information

To test the possible source of the HBV infection outside the study family, we searched the Genbank

To test the possible source of the HBV infection outside the study family, we searched the Genbank Supplementary Discussion The source of hepatitis B virus infection To test the possible source of the HBV infection outside the study family, we searched the Genbank and HBV Database (http://hbvdb.ibcp.fr),

More information

Natural History of Chronic Hepatitis B

Natural History of Chronic Hepatitis B Natural History of Chronic Hepatitis B Anna SF Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor,

More information

Wang et al. BMC Infectious Diseases (2016) 16:498 DOI /s

Wang et al. BMC Infectious Diseases (2016) 16:498 DOI /s Wang et al. BMC Infectious Diseases (2016) 16:498 DOI 10.1186/s12879-016-1834-2 RESEARCH ARTICLE Prevalence of hepatitis B surface antigen (HBsAg) in a blood donor population born prior to and after implementation

More information

Impact of Testing Strategies to Reduce Transmission Risk for HBV. Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013

Impact of Testing Strategies to Reduce Transmission Risk for HBV. Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013 Impact of Testing Strategies to Reduce Transmission Risk for HBV Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013 Overview of SANBS SANBS is a private not for profit company

More information

Clinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL

Clinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL Clinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL The World Health Organisation recent initiatives on HBV infection Launching of the

More information

Viral Hepatitis Diagnosis and Management

Viral Hepatitis Diagnosis and Management Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents

More information

4th International HIV/Viral Hepatitis Co-Infection Meeting

4th International HIV/Viral Hepatitis Co-Infection Meeting 4th International HIV/Viral Hepatitis Co-Infection Meeting The Rocky Road to Viral Hepatitis Elimination: Assuring access to antiviral therapy for ALL co-infected patients from low to high income settings

More information

Occult Hepatitis B Infection: why, who and what to do?

Occult Hepatitis B Infection: why, who and what to do? Occult Hepatitis B Infection: why, who and what to do? MF Yuen, MD, PhD Chair of Gastroenterology and Hepatology Department of Medicine The University of Hong Kong Queen Mary Hospital, Hong Kong Who? Different

More information

Natural History of HBV Infection

Natural History of HBV Infection Natural History of HBV Infection Joseph JY Sung MD PhD Institute of Digestive Disease Department of Medicine & Therapeutics Prince of Wales Hospital The Chinese University of Hong Kong HBV Infection 2

More information

Basics of hepatitis B diagnostics. Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology

Basics of hepatitis B diagnostics. Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology Basics of hepatitis B diagnostics Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology Basics of hepatitis B diagnostics Background Epidemiology Morphology Life-cycle Diagnostic markers

More information

Micropathology Ltd. University of Warwick Science Park, Venture Centre, Sir William Lyons Road, Coventry CV4 7EZ

Micropathology Ltd. University of Warwick Science Park, Venture Centre, Sir William Lyons Road, Coventry CV4 7EZ www.micropathology.com info@micropathology.com Micropathology Ltd Tel 24hrs: +44 (0) 24-76 323222 Fax / Ans: +44 (0) 24-76 - 323333 University of Warwick Science Park, Venture Centre, Sir William Lyons

More information

An Update HBV Treatment

An Update HBV Treatment An Update HBV Treatment Epidemiology Natural history Treatment Daryl T.-Y. Lau, MD, MPH Associate Professor of Medicine Director of Translational Liver Research Division of Gastroenterology BIDMC, Harvard

More information

HBV. Next Generation Sequencing, data analysis and reporting. Presenter Leen-Jan van Doorn

HBV. Next Generation Sequencing, data analysis and reporting. Presenter Leen-Jan van Doorn HBV Next Generation Sequencing, data analysis and reporting Presenter Leen-Jan van Doorn HBV Forum 3 October 24 th, 2017 Marriott Marquis, Washington DC www.forumresearch.org HBV Biomarkers HBV biomarkers:

More information

Cornerstones of Hepatitis B: Past, Present and Future

Cornerstones of Hepatitis B: Past, Present and Future Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related

More information

CDC website:

CDC website: Hepatitis B virus CDC website: http://www.cdc.gov/ncidod/diseases/hepatitis/slideset/hep_b/slide_1.htm Relevance Key Features es of Hepatitis t B Virus 250 million people infected worldwide. In areas of

More information

Hepatitis B viral safety of blood donations: new gaps identified

Hepatitis B viral safety of blood donations: new gaps identified Editorial Page 1 of 5 Hepatitis B viral safety of blood donations: new gaps identified Wolfram H. Gerlich, Dieter Glebe, Christian G. Schüttler Institute of Medical Virology, National Reference Centre

More information

Y. Xiang*, P. Chen*, J.R Xia and L.P. Zhang

Y. Xiang*, P. Chen*, J.R Xia and L.P. Zhang A large-scale analysis study on the clinical and viral characteristics of hepatitis B infection with concurrence of hepatitis B surface or E antigens and their corresponding antibodies Y. Xiang*, P. Chen*,

More information

DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA - UPDATE

DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA - UPDATE DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA - UPDATE SoGAT Clinical Diagnostics III 12-13 January 2011, London Michael Chudy Julia Kreß Micha Nübling Paul-Ehrlich-Institut

More information

risk of Transfusion-Transmitted Transmitted Viral Infections (HIV, HCV and HBV)

risk of Transfusion-Transmitted Transmitted Viral Infections (HIV, HCV and HBV) Prevention and ResidualR risk of Transfusion-Transmitted Transmitted Viral Infections (HIV, HCV and HBV) Syria Laperche L (Centre National de référence r rence pour les hépatites h B et C en Transfusion)

More information

HBV Biology a light(e)ning tour

HBV Biology a light(e)ning tour HBV Biology a light(e)ning tour J02203 X59795 X65257 7 G mut BDM8 54 Q mut 265 M mut M32138 AF214660 BDTF10 BD B2 BD B5 25 ARR mut BD B1 BDH3 BDH4 BDH7 BDH5 BDQ8 X65259 BDQ3 BDR5 BDM3 10 228 R mut BDQ15

More information

Characterization of Hepatitis B Virus (HBV) Among Liver Patients in Kenya

Characterization of Hepatitis B Virus (HBV) Among Liver Patients in Kenya Characterization of Hepatitis B Virus (HBV) Among Liver Patients in Kenya By MISSIANI OCHWOTO (Medical Research officer, KEMRI) Julius Oyugi 2, Dufton Mwaengo 2, James Kimotho 1 Carla Osiowy 3 and Elijah

More information

HBV Core and Core-Related Antigen Quantitation in Chinese Patients with. Chronic Hepatitis B Genotype B and C Virus Infection

HBV Core and Core-Related Antigen Quantitation in Chinese Patients with. Chronic Hepatitis B Genotype B and C Virus Infection Title page HBV Core and Core-Related Antigen Quantitation in Chinese Patients with Chronic Hepatitis B Genotype B and C Virus Infection Short Title: Quantitation of HBc and HBcrAg in Chinese patients Akinori

More information

WHO Parvovirus B19 Genotype Panel

WHO Parvovirus B19 Genotype Panel WHO Parvovirus B19 Genotype Panel Mei-ying W Yu, PhD SoGAT XXII Rome, 14-15 April 2011 1 st WHO International Reference Panel for Parvovirus B19 Genotypes In Oct 2009, a plasma-derived parvovirus B19 (B19V)

More information

HBV : Structure. HBx protein Transcription activator

HBV : Structure. HBx protein Transcription activator Hepatitis B Virus 1 Hepatitis B Virus 2 Properties of HBV a member of the hepadnavirus group Enveloped, partially double-stranded DNA viruses, smallest DNA virus Replication involves a reverse transcriptase

More information

NATURAL HISTORY OF HEPATITIS B

NATURAL HISTORY OF HEPATITIS B NATURAL HISTORY OF HEPATITIS B AND DIAGNOSTIC: STATE OF THE ART O. BAHRI LABORATORY OF MEDICAL BIOLOGY AZIZA OTHMANA HOSPITAL TUNIS, TUNISIA The 2 nd Congress of The Federation of Arab Societies of Clinical

More information

Alla ricerca del virus nascosto (quando il virus dell epatitie B si occulta )

Alla ricerca del virus nascosto (quando il virus dell epatitie B si occulta ) Alla ricerca del virus nascosto (quando il virus dell epatitie B si occulta ) Giovanni Raimondo Epatologia Clinica e Biomolecolare Policlinico Universitario di Messina UI/ml pg/ml HBsAg HBeAg + anti-hbe

More information

2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies

2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies 2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies Submitted by: Malaysia Policy Dialogue and Workshop on Attaining a Safe and Sustainable Blood Supply Chain Manila, Philippines 30 September 1

More information

COMPARISON OF HBV RIBONUCLEASE H DOMAIN IN NAÏVE AND DRUG RESISTANT PATIENTS

COMPARISON OF HBV RIBONUCLEASE H DOMAIN IN NAÏVE AND DRUG RESISTANT PATIENTS HBV RIBONUCLEASE H DOMAIN IN PATIENTS WITH DRUG RESISTANT COMPARISON OF HBV RIBONUCLEASE H DOMAIN IN NAÏVE AND DRUG RESISTANT PATIENTS Surachai Amornsawadwattana, Pattaratida Sa-Nguanmoo, Preeyaporn Vichaiwattana,

More information

Title: Reactivation of a Hepatitis B without core antibody: a case report.

Title: Reactivation of a Hepatitis B without core antibody: a case report. JCM Accepted Manuscript Posted Online 28 January 2015 J. Clin. Microbiol. doi:10.1128/jcm.03546-14 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 1 Title: Reactivation of a Hepatitis

More information

Clinical and Virological Characteristics of Chronic Hepatitis B Patients with Coexistence of HBsAg and Anti-HBs

Clinical and Virological Characteristics of Chronic Hepatitis B Patients with Coexistence of HBsAg and Anti-HBs RESEARCH ARTICLE Clinical and Virological Characteristics of Chronic Hepatitis B Patients with Coexistence of HBsAg and Anti-HBs Yong Liu 1,2, Le Zhang 1,2, Jin-Yong Zhou 1,2, Jinshun Pan 1,2, Wei Hu 1,

More information

AccuVert HBV Seroconversion Panel PHM941(M) ( )

AccuVert HBV Seroconversion Panel PHM941(M) ( ) PACKAGE INSERT PHM941(M) (0605-0061) INTENDED USE PHM941(M) (0605-0061) is a group of serial bleeds from an individual plasma donor during HBV seroconversion. This panel is intended for use by diagnostics

More information

Test Name Results Units Bio. Ref. Interval

Test Name Results Units Bio. Ref. Interval LL - LL-ROHINI (NATIONAL REFERENCE 135091606 Age 24 Years Gender Male 30/8/2017 92800AM 30/8/2017 94631AM 31/8/2017 90306AM Ref By Final HEATITIS A & B VIRUS EVALUATION HEATITIS A ANTIBODY (ANTI HAV),

More information

Bible Class: Hepatitis B Virus Infection

Bible Class: Hepatitis B Virus Infection Bible Class: Hepatitis B Virus Infection Nasser Semmo UVCM, Hepatology What is the HBV prevalence? 2 Hepatitis B Worldwide approx. 350 Mio. chronically infected with HBV Approx. 40% of the world population:

More information

SEROLOGICAL STATUS OF HEPATITIS B VIRUS INFECTION AMONG MONKS AND NOVICES AT BUDDHIST MONASTERIES IN THREE TOWNSHIPS, YANGON

SEROLOGICAL STATUS OF HEPATITIS B VIRUS INFECTION AMONG MONKS AND NOVICES AT BUDDHIST MONASTERIES IN THREE TOWNSHIPS, YANGON SEROLOGICAL STATUS OF HEPATITIS B VIRUS INFECTION AMONG MONKS AND NOVICES AT BUDDHIST MONASTERIES IN THREE TOWNSHIPS, YANGON Moe Pwint 1, Aye Marlar Win 1, Wah Win Htike 1, Khine Khine Su 2, Wai Wai Min

More information

Routine Use of Mini-Pool Nucleic Acid Testing (MP-NAT) Multiplex Assay for Sero-Negative Blood Donors

Routine Use of Mini-Pool Nucleic Acid Testing (MP-NAT) Multiplex Assay for Sero-Negative Blood Donors Journal of the Egyptian Society of Haematology & Research, Vol. 7, No. 2, September: 1-5, 2011 Routine Use of Mini-Pool Nucleic Acid Testing (MP-NAT) Multiplex Assay for Sero-Negative Blood Donors HISHAM

More information

Received 30 May 2004/Returned for modification 6 August 2004/Accepted 12 August 2004

Received 30 May 2004/Returned for modification 6 August 2004/Accepted 12 August 2004 JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 2004, p. 5036 5040 Vol. 42, No. 11 0095-1137/04/$08.00 0 DOI: 10.1128/JCM.42.11.5036 5040.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.

More information

Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics

Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Hepadnaviruses Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Hepatitis viruses A group of unrelated pathogens termed hepatitis viruses cause the vast majority

More information

NAT Screening of Blood Donations in NBC, TRCS

NAT Screening of Blood Donations in NBC, TRCS IPFA/PEI, Italy NAT Screening of Blood Donations in NBC, TRCS 2000-2001 Clinical evaluation using COBAS AmpliiScreen HIV & HCV assays, (MP24) window period rate - 1 : 108,768 for HIV-1 and HCV 2002 Routine

More information

Molecular genetic characterization of hepatitis epidemiology in Latvia Irina Somiskaya Paul Pumpens

Molecular genetic characterization of hepatitis epidemiology in Latvia Irina Somiskaya Paul Pumpens Molecular genetic characterization of hepatitis epidemiology in Latvia Irina Somiskaya Paul Pumpens Riga 2015 Sequencing of viral genes and complete viral genomes Results in: identification of viral genotype/subtype/mutants

More information

New (Virological) Tools for Testing and Monitoring Hepatitis B and C

New (Virological) Tools for Testing and Monitoring Hepatitis B and C New (Virological) Tools for Testing and Monitoring Hepatitis B and C Professor Stephen Locarnini WHO Regional Reference Centre for Hepatitis B Victorian Infectious Diseases Reference Laboratory, Doherty

More information

UvA-DARE (Digital Academic Repository) Residual infectious risks in blood transfusion Lieshout-Krikke, R.W. Link to publication

UvA-DARE (Digital Academic Repository) Residual infectious risks in blood transfusion Lieshout-Krikke, R.W. Link to publication UvA-DARE (Digital Academic Repository) Residual infectious risks in blood transfusion Lieshout-Krikke, R.W. Link to publication Citation for published version (APA): Lieshout-Krikke, R. W. (2016). Residual

More information

Isolated Hepatitis B Core Antibody

Isolated Hepatitis B Core Antibody NORTHWEST AIDS EDUCATION AND TRAINING CENTER Isolated Hepatitis B Core Antibody Nina Kim, MD MSc Associate Professor of Medicine November 13, 2014 Isolated Core Antibody Virology & terminology Definition

More information

Professor Vincent Soriano

Professor Vincent Soriano Five Nations Conference on HIV and Hepatitis in partnership with Professor Vincent Soriano Hospital Carlos III, Madrid, Spain Professor Vincent Soriano in partnership with Hospital Carlos III, Madrid,

More information

Understanding HBV Testing: HBsAg, HBV RNA, cccdna, HBeAg and HBcrAg in Context of Antiviral Drug Development

Understanding HBV Testing: HBsAg, HBV RNA, cccdna, HBeAg and HBcrAg in Context of Antiviral Drug Development Understanding HBV Testing: HBsAg, HBV RNA, cccdna, HBeAg and HBcrAg in Context of Antiviral Drug Development Professor Stephen Locarnini WHO Regional Reference Centre for Hepatitis B Victorian Infectious

More information

Hepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University

Hepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph

More information

Trends in molecular diagnostics

Trends in molecular diagnostics Trends in molecular diagnostics Detection of target genes of interest Quantification Infectious diseases HIV Hepatitis C & B TB / MAC Cytomegalovirus Herpes simplex Varicella zoster CT/GC HPV Profiling

More information

HBV NATURAL HISTORY. Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia

HBV NATURAL HISTORY. Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia HBV NATURAL HISTORY AND MANAGMENT Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia IVer Liver Institute of Virginia Education,

More information

IDENTIFICATION OF HEPATITIS B VIRUS VERTICAL TRANSMISSION FROM FATHER TO FETUS BY DIRECT SEQUENCING

IDENTIFICATION OF HEPATITIS B VIRUS VERTICAL TRANSMISSION FROM FATHER TO FETUS BY DIRECT SEQUENCING SOUTHEAST ASIAN J TROP MED PUBLIC HEALTH IDENTIFICATION OF HEPATITIS B VIRUS VERTICAL TRANSMISSION FROM FATHER TO FETUS BY DIRECT SEQUENCING Shanshan Wang, Guifu Peng, Mimin Li, Hong Xiao, Pulin Jiang,

More information

Test Name Results Units Bio. Ref. Interval

Test Name Results Units Bio. Ref. Interval LL - LL-ROHINI (NATIONAL REFERENCE 135091650 Age 49 Years Gender Male 29/8/2017 120000AM 29/8/2017 100248AM 29/8/2017 105306AM Ref By Final HEATITIS, VIRAL, COMREHENSIVE ANEL HEATITIS A ANTIBODY (ANTI

More information

Hepatitis A-E Viruses. Dr Nemes Zsuzsanna

Hepatitis A-E Viruses. Dr Nemes Zsuzsanna Hepatitis A-E Viruses Dr Nemes Zsuzsanna Viral Hepatitis - Historical Perspectives Infectious A E Enterically transmitted Viral hepatitis NANB Serum B D C Parenterally transmitted HGV, TTV, SEN, other

More information

WHO GUIDELINES ON ESTIMATION OF RESIDUAL RISK OF HIV, HBV OR HCV INFECTIONS VIA CELLULAR BLOOD COMPONENTS AND PLASMA

WHO GUIDELINES ON ESTIMATION OF RESIDUAL RISK OF HIV, HBV OR HCV INFECTIONS VIA CELLULAR BLOOD COMPONENTS AND PLASMA ENGLISH ONLY EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 17 to 21 October 2016 WHO GUIDELINES ON ESTIMATION OF RESIDUAL RISK OF HIV, HBV OR HCV INFECTIONS VIA CELLULAR BLOOD COMPONENTS AND PLASMA

More information

Since 1973 all blood donations in the Netherlands

Since 1973 all blood donations in the Netherlands ORIGINAL RESEARCH Rare transmission of hepatitis B virus by Dutch donors with occult infection Ryanne W. Lieshout-Krikke, 1 Marian G.J. van Kraaij, 2 Fikreta Danovic, 2 and Hans L. Zaaijer 1 BACKGROUND:

More information

THE IMPACT OF HLA CLASS I ON VIROLOGICAL OUTCOMES OF HBV

THE IMPACT OF HLA CLASS I ON VIROLOGICAL OUTCOMES OF HBV THE IMPACT OF HLA CLASS I ON VIROLOGICAL OUTCOMES OF HBV Philippa Matthews Consultant in Infectious Diseases & Microbiology SUPPRESSION CO-EVOLUTION ESCAPE Host factors associated with the clinical course

More information

Prediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term 2015

Prediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term 2015 THAI J 16 GASTROENTEROL Treatment with Nucleos(t)ide Original Analogues Article Prediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term Treatment with Nucleos(t)ide Analogues Sombutsook

More information

Sequence analysis for VP4 of enterovirus 71 isolated in Beijing during 2007 to 2008

Sequence analysis for VP4 of enterovirus 71 isolated in Beijing during 2007 to 2008 16 2009 3 4 1 Journal of Microbes and Infection, March 2009, Vol. 4, No. 1 2007 2008 71 VP4 1, 2, 2, 2, 1, 2, 2, 2, 1, 2 1., 100730; 2., 100020 : 2007 2008 71 ( EV71), 2007 3 EV71( 1, 2 ) 2008 5 EV71(

More information

Acute Hepatitis B Virus Infection with Recovery

Acute Hepatitis B Virus Infection with Recovery Hepatitis B: Clear as Mud Melissa Osborn, MD, MSCR Assistant Professor Emory University School of Medicine Atlanta, GA 1 Objectives 1. Distinguish the various stages in the natural history of chronic hepatitis

More information

HBsAg(+) mothers is a transient

HBsAg(+) mothers is a transient Perinatal HBV viremia in newborns of HBsAg(+) mothers is a transient phenomenon that does not necessarily imply HBV infection transmission Vana Papaevangelou (Greece) National and Kapodistrian University

More information

CURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia

CURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia CURRENT TREATMENT OF HBV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia CHRONIC HBV INFECTION DEMOGRAPHICS IN THE USA Estimated

More information

Hepatitis B New Therapies

Hepatitis B New Therapies Hepatitis B New Therapies Richard K. Sterling, MD, MSc, FACP, FACG, FAASLD, AGAF VCU Hepatology Professor of Medicine Chief, Section of Hepatology Fellowship Director, Transplant Hepatology Virginia Commonwealth

More information

Multi-clonal origin of macrolide-resistant Mycoplasma pneumoniae isolates. determined by multiple-locus variable-number tandem-repeat analysis

Multi-clonal origin of macrolide-resistant Mycoplasma pneumoniae isolates. determined by multiple-locus variable-number tandem-repeat analysis JCM Accepts, published online ahead of print on 30 May 2012 J. Clin. Microbiol. doi:10.1128/jcm.00678-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Multi-clonal origin

More information

What have we learned from HBV clinical cohorts?

What have we learned from HBV clinical cohorts? PHC 2015: Hepatitis B What have we learned from HBV clinical cohorts? Jia-Horng Kao MD, Ph D Graduate Institute of Clinical Medicine, Hepatitis Research Center, Department of Internal Medicine, National

More information

NH2 N N N O N O O P O O O O O

NH2 N N N O N O O P O O O O O N N NH 2 N N O O P O O O O O O James Watson and Francis Crick Double Helix 1953 Baruch Blumberg, MD, PhD 1925-2011 Australia Antigen 1965 Hepatitis B Virus (HBV) Hepadnaviridae member that primarily infects

More information

Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads. Hepatology Feb 2013

Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads. Hepatology Feb 2013 Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads Hepatology Feb 2013 Hepatitis B Surface Antigen HBsAg is the glycosylated envelope

More information

The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P

The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P Record Status This is a critical abstract of an economic evaluation that meets

More information

Journal of Microbes and Infection,June 2007,Vol 2,No. 2. (HBsAg)2 , (PCR) 1762/ 1764

Journal of Microbes and Infection,June 2007,Vol 2,No. 2. (HBsAg)2 , (PCR) 1762/ 1764 68 2007 6 2 2 Journal of Microbes and Infection,June 2007,Vol 2,No. 2 2 S 1 1 1 2 2 3 1 (HBsAg)2 ( YIC) S 5 30g 60g YIC ( HBV) DNA > 2 log10 e (HBeAg), 6 DNA, 1 YIC 1, (PCR) (0 ) (44 ) HBV DNA S 2, S a

More information

Hepatitis B. Hepatitis Viruses. Hepatitis Viruses. Hepatitis Viruses

Hepatitis B. Hepatitis Viruses. Hepatitis Viruses. Hepatitis Viruses Hepatitis Viruses Hepatitis B History and Overview of Hepatitis B Testing in Australia Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Cytomegalovirus Epstein-Barr Virus Hepatitis Viruses Hepatitis

More information

Donor Screening in The Region. Vincini GA NRL, Melbourne, Australia

Donor Screening in The Region. Vincini GA NRL, Melbourne, Australia Donor Screening in The Region Vincini GA NRL, Melbourne, Australia NRL Established in 1985 Not-for-profit organisation that exists to support laboratories that perform testing for the diagnosis and management

More information

Pathological Features and Prognosis in Chronic Hepatitis B Virus Carriers

Pathological Features and Prognosis in Chronic Hepatitis B Virus Carriers The Journal of International Medical Research 2011; 39: 71 77 Pathological Features and Prognosis in Chronic Hepatitis B Virus Carriers ZH LU, W CHEN, ZC JU, H PEI, XJ YANG, XB GU AND LH HUANG Department

More information

In October 2005, the South African National Blood

In October 2005, the South African National Blood DONOR INFECTIOUS DISEASE TESTING Hepatitis B virus transmission by blood transfusion during 4 years of individual-donation nucleic acid testing in South Africa: estimated and observed window period risk_3355

More information

La riattivazione dell epatite virale nel paziente in terapia biologica

La riattivazione dell epatite virale nel paziente in terapia biologica La riattivazione dell epatite virale nel paziente in terapia biologica Claudio Puoti S.C. di Medicina Interna e Medicina Epato-Gastroenterologica Osp. di Marino-Frascati - Roma Patterns of HBV-related

More information

Infectious Disease Testing. ULTRA Product Line. Safety is not a Matter of Chance

Infectious Disease Testing. ULTRA Product Line. Safety is not a Matter of Chance Infectious Disease Testing ULTRA Product Line Safety is not a Matter of Chance ULTRA Product Line The best answer for HBV, HCV and HIV screening: a global automated solution for safe results. Monolisa

More information

AccuSet HBV Worldwide Performance Panel

AccuSet HBV Worldwide Performance Panel PACKAGE INSERT 0805-033 INTENDED USE The is intended for use by diagnostic manufacturers, researchers, and clinical laboratories to develop, evaluate, or troubleshoot HBV test methods. Characterized samples

More information

The ABC s (and D & E s) of the Viral Hepatitides Part 2 DIAGNOSTIC TESTS 3/7/2013

The ABC s (and D & E s) of the Viral Hepatitides Part 2 DIAGNOSTIC TESTS 3/7/2013 The ABC s (and D & E s) of the Viral Hepatitides Part 2 Thomas Novicki PhD DABMM Clinical Microbiologist Division of Laboratory Medicine novicki.thomas@marshfieldclinic.org Objectives 2 1. Explain the

More information

Learning Objectives: Hepatitis Update. Primary Causes of Chronic Liver Disease in the U.S. Hepatitis Definition. Hepatitis Viruses.

Learning Objectives: Hepatitis Update. Primary Causes of Chronic Liver Disease in the U.S. Hepatitis Definition. Hepatitis Viruses. Learning Objectives: Hepatitis Update ASCLS-Michigan March 31, 2016 Dr. Kathleen Hoag Upon attendance of this seminar and review of material provided, the attendees will be able to: 1. List hepatitis viruses

More information

on January 29, 2019 by guest

on January 29, 2019 by guest CVI Accepts, published online ahead of print on 21 March 2012 Clin. Vaccine Immunol. doi:10.1128/cvi.05696-11 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10

More information

ARTICLE IN PRESS. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update

ARTICLE IN PRESS. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:xxx REVIEW A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update EMMET B. KEEFFE,* DOUGLAS T. DIETERICH,

More information

Hepatitis B Virus infection: virology

Hepatitis B Virus infection: virology Hepatitis B Virus infection: virology 167 Falk Symposium: Liver under constant attack from fat to viruses III Falk Gastro-Konferenz 17.-21. September 2008 Congress Centrum Mainz Maura Dandri Department

More information

[DOI] /j.issn , China

[DOI] /j.issn , China Med J Chin PLA, Vol. 41, No. 5, May 1, 2016 351 HBsAg HBs S N- [ ] (HBV)HBsAg+ HBs S (MHR) N- HBsAg+ HBs 284 HBsAg+ HBs 314 HBsAg HBV S 1 MHR N- N- S/S HepG2 HBsAg+ HBs MHR N- 11.3%(32/284) HBsAg 2.9%(9/314)(P

More information

The ABCs of Viral Hepatitis Diagnosis. Ila Singh, M.D., Ph.D. P & S Viral Hepatitis. Hepatitis A, B, C, D, E and G viruses

The ABCs of Viral Hepatitis Diagnosis. Ila Singh, M.D., Ph.D. P & S Viral Hepatitis. Hepatitis A, B, C, D, E and G viruses The ABCs of Viral Hepatitis Diagnosis Ila Singh, M.D., Ph.D. P & S 14-453 is132@columbia.edu Viral Hepatitis Hepatotropic viruses Hepatitis A, B, C, D, E and G viruses Generalized infection plus infection

More information

Immune pressure analysis of protease and reverse transcriptase genes of primary HIV-1 subtype C isolates from South Africa

Immune pressure analysis of protease and reverse transcriptase genes of primary HIV-1 subtype C isolates from South Africa African Journal of Biotechnology Vol. 10(24), pp. 4784-4793, 6 June, 2011 Available online at http://www.academicjournals.org/ajb DOI: 10.5897/AJB10.560 ISSN 1684 5315 2011 Academic Journals Full Length

More information

Investigation into withdrawal of entecavir after 20 months in an HBsAb-positive patient who received HBsAg allogeneic stem cell transplantation

Investigation into withdrawal of entecavir after 20 months in an HBsAb-positive patient who received HBsAg allogeneic stem cell transplantation Investigation into withdrawal of entecavir after 20 months in an HBsAb-positive patient who received HBsAg allogeneic stem cell transplantation J. Peng, W.F. Luo, B. Zhou and W.Q. Wen Department of Infectious

More information

5. Over the last ten years, the proportion of HIV-infected persons who are women has: a. Increased b. Decreased c. Remained about the same 1

5. Over the last ten years, the proportion of HIV-infected persons who are women has: a. Increased b. Decreased c. Remained about the same 1 Epidemiology 227 April 24, 2009 MID-TERM EXAMINATION Select the best answer for the multiple choice questions. There are 60 questions and 9 pages on the examination. Each question will count one point.

More information

JMSCR Volume 03 Issue 01 Page January 2015

JMSCR Volume 03 Issue 01 Page January 2015 www.jmscr.igmpublication.org Impact Factor 3.79 ISSN (e)-2347-176x Seroprevalence of HBV among HIV Patients and Blood Donors Author Dr. Vedavati B I 1, Dr. Amrutha Kumari B 2, Dr. Venkatesha D 3 Mysore

More information

Impact of multi-dye multiplex technology on testing algorithm

Impact of multi-dye multiplex technology on testing algorithm Impact of multi-dye multiplex technology on testing algorithm Lydia Blanco. Mª Isabel Gonzalez-Fraile Centro de Hemoterapia y Hemodonación de Castilla y León, España TTI EPIDEMIOLOGICAL DATA IN SPAIN NAT

More information

Hepatitis B Antiviral Drug Development Multi-Marker Screening Assay

Hepatitis B Antiviral Drug Development Multi-Marker Screening Assay Hepatitis B Antiviral Drug Development Multi-Marker Screening Assay Background ImQuest BioSciences has developed and qualified a single-plate method to expedite the screening of antiviral agents against

More information

HEPATITIS VIRUSES. Other causes (not exclusively hepatitis v.)also called sporadic hepatitis: HEPATITIS A(infectious hepatitis)

HEPATITIS VIRUSES. Other causes (not exclusively hepatitis v.)also called sporadic hepatitis: HEPATITIS A(infectious hepatitis) Dept.of Microbiology/Virology Assist.prof. Shatha F. Abdullah HEPATITIS VIRUSES Medically important hepatitis v. (liver)are: 1.HAV 2.HBV 3.HCV 4.HDV 5.HEV 6.HGV Other causes (not exclusively hepatitis

More information